anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Only ADT as background treatment without Darolutamide. PSA check every three months, when the patient's PSA \> 1ng/ml (or PSA \> 1ng/ml and PSA has risen by more than 20% comparing baseline), restart the darolutamide, until mCRPC.
Low Back Pain is a major cause of disability worldwide, affecting both genders equally at some point in their lives. 95% of low back pain is mechanical in origin which is the pain originating from spine, intervertebral discs and surrounding soft tissue structures. A total of 50 participants will be divided into two groups by coin toss method, based on the eligibility criteria. Baseline assessment of pain using NPRS, range of motion using Gravity-Based Inclinometer and disability using Oswestry Disability Index will be done on 1st session for both the groups. Group A will be receiving moist heat for 10 minutes followed by myofascial release and post-treatment stretching. Whereas, on the other hand, Group B will be receiving moist heat for 10 minutes followed by Instrument Assisted Soft Tissue Mobilization using Graston G6 long bar tool for 5-7 minutes with gentle horizontal stroking at an angle of 45 degrees over lumbar area followed by post-treatment stretching. Total treatment plan will be of 3 weeks, consisting of total 9 sessions, 3 sessions on alternate days. Final assessment will be done for pain, range of motion and disability on last session at 3rd week. Gentle icing would be recommended in case of itching and bruising over the treated area.
Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
PROBLEM TO BE SOLVED: To obtain the subject new compound exhibiting antifungal action and useful as a therapeutic medicine for fungal infectious diseases. SOLUTION: This compound F-10778 is represented by the formula. The compound F-10778 is obtained by subjecting Tapesia sp. SANK 18896 strain to culture, preferably shaking culture at 22-26 deg.C, e.g. 23 deg.C for several days. Carbon source (e.g. glucose or fructose) and nitrogen source (e.g. soybean flour, wheat bran or peanut flour) can be used in combination as the culture medium at growing stage of species. Amount of production of the objective compound attains maximum value by culturing the fungus for 120-200 hr. After culture is finished, the fungal cell and solid part are fractionated by filtration operation or the like and purified by extraction. The compound is orally administered, e. g. in the case of tablet, pill, powder, granule or the like and intravenously administered in the case of injection.  The amount of an active ingredient compound contained in the pharmaceutical preparation is preferably 1-30 wt.% based on total composition. The daily dose of the active ingredient is preferably 0.1-20 mg/adult.
PURPOSE: An antiviral composition containing Salmonella strain which expresses hemagglutin protein is provided to ensure synergistic antiviral effect. CONSTITUTION: A samonella strain which expresses hemagglutin protein contains a hemagglutin antigen gene. The hemagglutin antigen gene is inserted and transduced to a plasmid which expresses hemagglutin protein. The plasmid is pcDNA3-HA. An attenuated Salmonella strain is Salmonella typhimurium BRD 509. The hemagglutin antigen gene has a base sequence of sequence number 1.
The study duration is 4 weeks long, during which subjects will undergo a 1 week run-in period followed by 3 randomized weeks of observational study. During the 1 week run-in period, subjects will familiarize themselves with the CGM and the other data collection procedures. Following the run-in week, the subject will be randomized to a specific order of observation weeks. The three observation weeks are a resistance training week, an aerobic exercise week and a control week with no explicit exercise. During the observation weeks, there will be 4 interventions planned, two during both the aerobic exercise and the resistance training week. See Schematic below for details. During both the aerobic exercise week intervention visits, subjects will exercise for \~45 minutes on a treadmill and during the resistance training week, subjects will perform strength training exercises for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The duration of the resistance training period is expected to be \~45min. Subjects will continue to perform daily activities during each of the weeks.

During each week, the subject will wear one subcutaneous DexcomTM G4 or DexcomTM G4 Share continuous glucose monitoring (CGM) system, one activity monitor- ActiGraph wGT3X-BT or ActiGraph GT9X, one insulin pump (subject's own pump) and one Samsung Galaxy S4 phone loaded with two applications- meal memory and moves. The CGM system will provide sensed glucose data every 5 minutes. The CGM data will be blinded to the patient to prevent any abrupt changes in behavior. The accuracy of the sensed data will be obtained by reference measurements of capillary blood glucose. The activity monitor will be secured on the dominant wrist and uses an accelerometer to collect movement data at a high frequency (80Hz). The activity monitor measures both motion and ambient light, this data would be used to determine the various sleep quality measures. The subject's insulin dosage information from the pump will be downloaded for data analysis purposes. The subject's daily meal intake (photographic log and note diary) and daily movement pattern information will be downloaded from the phone. During the 4 exercise intervention visits, subject's heart rate, accelerometry information from the torso and oxygen consumption measured breath by breath may be collected for data analysis purposes.
Traumatic brain injury (TBI) is a leading cause of mortality and morbidity and one of the greatest unmet needs in public health. The most severe injury can lead to a poor outcome and prolonged coma of the victims. It is estimated that ten to fifteen percent of the severe TBI patients are discharged in a prolonged coma or a vegetative state. However, no treatment measure to data has been proven robustly to alter the pace of recovery or improve neurological outcome of the comatose patients following TBI.

Although right median nerve electrical stimulation (RMNS) has been used clinically for more than two decades, no strong evidence of efficacy was generated because of the limitations in the past trials including a small sample size or the inappropriate study design. In the present study, a multicenter research network with inclusion of neurotrauma centers from China, India, Nepal and Kazakhstan was established with the aim to validate the efficacy and safety of a promising intervention strategy for traumatic coma at early stage. Since RMNS is a simple, inexpensive, noninvasive technique with a good safety profile, our study will probably add more evidence to the treatment of traumatic coma in Asian countries.
ADHD (attention deficit hyperactivity disorder) is a common neurodevelopmental disorder characterized by hyperactivity, impulsivity, and inattention. Its prevalence ranges between 5.9 and 7.1% worldwide. Etiology of ADHD included combinations of genetic, neurological, and environmental factors. ADHD is more often a complex disorder with a high rate of associated comorbid conditions. Comorbid conditions are prevalent among people with ADHD and increase its burden and complexity of management. Children with ADHD are at a higher risk than children without ADHD for developing other psychiatric disorders. Most children with ADHD also have at least one comorbid condition, the presence of which contributes to poorer long-term outcomes. The pattern of comorbidities is influenced by age and sex; externalizing disorders are more common in younger ages and male participants, in contrast, internalizing disorders are more prevalent among older ages and female participants. Comorbidity involving ADHD and learning disorders is frequent, ranging from 25 to 40%. Other disorders likely to co-occur with ADHD are: bipolar disorders (11-75%), tic disorders (20%), obsessive compulsive disorders (6-15%). Children with ADHD may show several motor problems: longer and more variable reaction times, increased variability in speed and less accurate response reengagement, and impaired orienting responses, and increased number of responses with very long reaction times. Neurological soft sign have been associated with inattention and behavior difficulties for decades. Some researchers argue that these signs should be included in the diagnosis of ADHD.
The invention discloses a cough relieving cream. The cough relieving cream comprises the following ingredients in part by weight: 5-10 parts of loquat leaves, 3-7 parts of licorice, 1-2 parts of wolfberry, 2-3 parts of mulberry leaves, 2-3 parts of pinellia ternate , 2-4 parts of forsythia, 1-4 parts of pericarpium citri reticulatae, 2-4 parts of radix stemonae, 1-2 parts of cynanchum glaucescens, 1-2 parts of schizandra, 1-2 parts of snow pear and 1-2 parts of rock candy. The cough relieving cream is prepared by adding cough relieving and phlegm resolving drugs on the basis of a lung nourishing and cough relieving cream having the functions of tonifying the spleen, nourishing the lung and strengthening the kidney. The cough relieving cream has great therapeutic effects in clinic application and further has the preventive function. The cough relieving cream is convenient to take, does not have side effect and has remarkable therapeutic effect. The preparing method for the cough relieving cream is simple, convenient to operate and favorable to popularization.
Compositions and methods useful for treating nasal, neurological or psychiatric disorders and conditions are disclosed. The nasal, neurological or psychiatric discomfort or condition may be one that affects normal human neural sensory, neurocognitive or neuropsychiatric function, including but not limited to olfactory dysfunction. Discomfort or conditions may be associated with 2019 coronavirus disease (COVID-19), including but not limited to olfactory dysfunction. Compositions comprising vitamin a solution and an essential oil mixture are disclosed. The vitamin a solution may be a vitamin a compound and a non-toxic solvent such as a pharmaceutically acceptable solvent or the like. The concentration of vitamin a compound may be from 10,000 International Units (IU) to 120,000 International Units (IU). The ratio of vitamin a solution to essential oil mixture in the composition may be from 4:1 to 1:4. The composition of the vitamin a solution and the essential oil mixture may be atomized and administered via the nose of the subject.
The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
BACKGROUND: Gestational weight gain (GWG) is a critical factor influencing maternal and fetal health. Excessive or insufficient GWG can lead to various complications, including gestational diabetes, hypertension, cesarean delivery, low birth weight, and preterm birth. This study aims to develop and evaluate machine learning models to predict GWG categories: below, within, or above recommended guidelines.
METHODS: We analyzed data from the Araraquara Cohort, Brazil, which comprised 1557 pregnant women with a gestational age of 19 weeks or less. Predictors included socioeconomic, demographic, lifestyle, morbidity, and anthropometric factors. Five machine learning algorithms (Random Forest, LightGBM, AdaBoost, CatBoost, and XGBoost) were employed for model development. The models were trained and evaluated using a multiclass classification approach. Model performance was assessed using metrics such as area under the ROC curve (AUC-ROC), F1 score and Matthew's correlation coefficient (MCC).
RESULTS: The outcomes were categorized as follows: GWG within recommendations (28.7%), GWG below (32.5%), and GWG above recommendations (38.7%). The XGBoost presented the best overall model, achieving an AUC-ROC of 0.79 for GWG within, 0.76 for GWG below, and 0.65 for GWG above. The LightGBM also performed well with an AUC-ROC of 0.79 for predicting GWG within recommendations, 0.76 for GWG below, and 0.624 for GWG above. The most important predictors of GWG were pre-gestational BMI, maternal age, glycemic profile, hemoglobin levels, and arm circumference.
CONCLUSION: Machine learning models can effectively predict GWG categories, offering a valuable tool for early identification of at-risk pregnancies. This approach can enhance personalized prenatal care and interventions to promote optimal pregnancy outcomes.
Mastocytosis in infants and children is an unusual disease characterized by an excess of mast cells in tissues. In pediatric onset mastocytosis, disease is usually localized to the skin and disease is considered to be of limited duration. However, a subset of children appear to develop a clinical picture resembling that observed in adults who have adult-onset disease. This study will focus on children with more severe mastocytosis in an attempt to define its pathogenesis, focusing on mutations and polymorphisms in genes regulating mast cell proliferation and survival to determine if they might contribute to this disease pattern. If severe pediatric-onset disease does not fit within the existing classification, new criteria of diagnosis must be proposed for the pediatric age group.

This study will examine children and young adults age birth to 21 years with pediatric-onset disease previously enrolled on NIAID mastocytosis protocols, or as a result of physician referral, which have disease more consistent with adult-onset disease or parameters associated with increased morbidity. The evaluation may include serum tryptase, blood count, bone marrow biopsy and aspirate, morphology and mutational analysis. Subjects may be asked to return in 12-24 months for assessment. If relevant mutation effecting mast cell growth and function are identified, such mutations will be sought in the biologic parents as appropriate, but only when such mutations are believed to be germ line (not somatic) mutations. This study will aid in the understanding of the characteristics of severe mastocytosis in the pediatric age group.
For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
Placebo control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 14.5 days.
Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
Safety and effectiveness in pediatric patients below the age of 12 have not been established.

The safety and efficacy of ORLISTAT have been evaluated in obese adolescent patients aged 12 to 16 years. Use of ORLISTAT in this age group is supported by evidence from adequate and well-controlled studies of ORLISTAT in adults with additional data from a 54-week efficacy and safety study and a 21-day mineral balance study in obese adolescent patients aged 12 to 16 years. Patients treated with ORLISTAT in the 54-week efficacy and safety study (64.8% female, 75% Caucasians, 18.8% Blacks, and 6.3% Other) had a mean reduction in BMI of 0.55 kg/m 2 compared with an average increase of 0.31 kg/m 2 in placebo-treated patients (p=0.001). In both adolescent studies, adverse effects were generally similar to those described in adults and included fatty/oily stool, oily spotting, and oily evacuation. In a subgroup of 152 ORLISTAT and 77 placebo patients from the 54-week study, changes in body composition measured by DEXA were similar in both treatment groups with the exception of fat mass, which was significantly reduced in patients treated with ORLISTAT compared to patients treated with placebo (-2.5 kg vs -0.6 kg, p=0.033). Because ORLISTAT can interfere with the absorption of fat-soluble vitamins, all patients should take a daily multivitamin that contains vitamins A, D, E, K, and beta-carotene. The vitamin supplement should be taken at least 2 hours before or after ORLISTAT [see  Dosage and Administration (2),  Warnings and Precautions (5.1), and  Clinical Pharmacology (12.3)] .

Plasma concentrations of orlistat and its metabolites M1 and M3 were similar to those found in adults at the same dose level. Daily fecal fat excretions were 27% and 7% of dietary intake in ORLISTAT and placebo treatment groups, respectively.
METHODS Study participants and data collection The Research Ethics Committee of Jazan University, Saudi Arabia gave its approval to this study (Ref No: 05/JUREC/14PT.2020). Prior to participation, each participant signed an informed consent form. All experiments were carried out in line with the Helsinki Declaration. A prospective study was conducted on 50 consecutive individuals (26 obese, 24 non-obese). People aged 70 years or older, or who had any orthopedic or neurological difficulties were excluded from the trial. People were informed about the trial and consented in writing. Following enrollment, participants were placed into two groups according to their BMI. Participants in Group A were obese, defined as having a BMI of \> 30 to \< 35 kg/m2. Participants in Group B were non-obese, defined as having a BMI of \> 25 to \< 29.9 kg/m2.

Subjective ratings and spirometry data were taken at baseline. All spirometry tests were performed in the sitting position using the Vitalograph 2120 in accordance with established guidelines. At least three times, the readings were taken, and the best result was used. A posttest spirometry was performed on day 4 and 7 postoperatively. A six-minute walk (6-MWT) test was conducted at baseline and on day 7 postoperatively. Patients were advised to walk back and forth on the walking path at their own pace for 6-MWT. They were given six minutes to cover as much ground as possible. When 4 and 2 minutes remained in the test, prompts were offered. We utilized the following standardized prompt: "You're down to the final two (or four) minutes. You are doing an excellent job. You may accelerate or decelerate at any time, maintain the same pace, or take a break if necessary. Simply attempt to travel as much distance as possible in the remaining time. You are doing an excellent job." After six minutes, the participant's total distance traveled was recorded, along with a Borg dyspnea scale rating. A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups.

Statistical analysis The descriptive variables are expressed as mean ± standard deviation. The effect of physiotherapy program on pulmonary function and 6-MWT was assessed using an independent t-test. To estimate the percentage increase or decrease of pulmonary function and distance during 6-MWT for obese and non-obese groups, the percent difference between baseline and posttest data was calculated and compared using an independent t-test. When the normality test failed, the Mann Whitney U test and analysis of variance on rank were used. Chi-square test was used for gender distribution. The results were considered statistically significant if p ≤ 0.05. Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS, Windows version-17.0, SPSS Chicago. IL, USA).
Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
The association between tobacco smoke exposure and sleep has been widely discussed, but the correlation between serum cotinine levels and sleep health outcomes in adolescents has not been well described. This study aimed to further evaluate the association between serum cotinine levels and sleep health outcomes in adolescents using data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018. This cross-sectional study included participants aged 16-19 years from the NHANES 2005-2018. A weighted multivariate logistic regression model was used for the primary analysis. A restricted cubic spline (RCS) model was employed to investigate the non-linear association between serum cotinine levels and trouble sleeping. Subgroup analyses based on population characteristics were also conducted. In total, 2630 participants were included, which are representative of the 11.5 million US adolescents. Higher serum cotinine levels (≥ 3 ng/ml) were significantly associated with trouble sleeping in the fully adjusted model (odds ratio [OR] 1.817). The RCS model revealed a non-linear relationship between serum cotinine levels and trouble sleeping. Subgroup analyses indicated that this relationship was consistent and stable across various population characteristics. Serum cotinine levels are associated with sleep health outcomes in adolescents, with high serum cotinine levels being linked to increased trouble sleeping and longer or shorter sleep duration.